In 2020, we expect M&A to focus on small and midsize pharma companies rather than consolidations of large companies like Bristol-Myers Squibb Co./Celgene Corp. or AbbVie Inc./Allergan PLC. Drug prices are frequently negotiated in a single-payer government system, and governments can decide to only provide insurance coverage for a biosimilar if the reference product is deemed too expensive. ), CCL Industries Inc., and Avery Dennison Corporation.What the report offers: Key Topics Covered: 1 Executive Summary2 Preface2.1 Abstract2.2 Stake Holders2.3 Research Scope2.4 Research Methodology2.5 Research Sources3 Market Trend Analysis3.1 Introduction3.2 Drivers3.3 Restraints3.4 Opportunities3.5 Threats3.6 Technology Analysis3.7 Emerging Markets3.8 Impact of COVID-194 Porters Five Forces Analysis4.1 Bargaining Power of Suppliers4.2 Bargaining Power of Buyers4.3 Threat of Substitutes4.4 Threat of New Entrants4.5 Competitive Rivalry5 Global Future-proof Pharma Labels Market, By Technology5.1 Introduction5.2 Sensing Labels5.3 Near-Field-Communication (NFC)5.4 Radio-Frequency Identification (RFID)6 Global Future-proof Pharma Labels Market, By Geography6.1 Introduction6.2 North America6.2.1 US6.2.2 Canada6.2.3 Mexico6.3 Europe6.3.1 Germany6.3.2 UK6.3.3 Italy6.3.4 France6.3.5 Spain6.3.6 Rest of Europe6.4 Asia-Pacific6.4.1 Japan6.4.2 China6.4.3 India6.4.4 Australia6.4.5 New Zealand6.4.6 South Korea6.4.7 Rest of Asia-Pacific6.5 South America6.5.1 Argentina6.5.2 Brazil6.5.3 Chile6.5.4 Rest of South America6.6 Middle East & Africa6.6.1 Saudi Arabia6.6.2 UAE6.6.3 Qatar6.6.4 South Africa6.6.5 Rest of Middle East & Africa7 Key Developments7.1 Agreements, Partnerships, Collaborations and Joint Ventures7.2 Acquisitions & Mergers7.3 New Product Launches7.4 Expansions7.5 Other Key Strategies8 Company Profiling8.1 UPM Raflatac, Inc.8.2 Loftware, Inc.8.3 Schreiner Group8.4 Covectra, Inc.8.5 NiceLabel (Euro Plus d.o.o. It also provides leaders with key questions and actions to consider in the year ahead. Advances to opioid litigation: We believe a broad opioid-related settlement is more likely in 2020, raising the potential for significant legal liabilities associated with the marketing and distribution of opioid products, but also less uncertainty. We have a negative outlook or CreditWatch placement on several pharmaceutical companies with exposure to opioid litigation, including Teva, Endo, and Mallinckrodt. )8.6 CCL Industries Inc.8.7 Avery Dennison CorporationFor more information about this report visit https://www.researchandmarkets.com/r/rezr15. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. The Chemical Pharmaceutical market report offers a holistic assessment of this industry vertical highlighting the key trends responsible for the growth across the regional contributors. Drug pricing reform is likely to occur eventually given the unsustainable growth in pharmaceutical spending (about 4%-5% annually). In September 2018, Novartis announced it would also sell its Sandoz U.S. dermatology business and generic U.S. oral solids portfolio, to refocus its business. Contrastingly, we expect to lower the rating on AbbVie to 'BBB+' after the close of its acquisition of Allergan, which we believe was partially motivated by biosimilar competition to Humira. We do not expect further consolidation. A year ago, we thought the bipartisan political rhetoric and social pressure would result in meaningful legislation in the near term related to drug rebates and government drug purchases. After one trial in Oklahoma, a flurry of settlements in two Ohio counties, and a proposed global settlement framework, we believe 2020 could bring more clarity to the range of outcomes in opioid litigation, especially for larger defendants. Pharmaceutical Contract Manufacturing Market Size 2020, Global Trends, Industry Analysis, Top Companies, Merger, Regional Outlook, Revenue September 9th, 2020 Market Research Future Releases The Content shall not be used for any unlawful or unauthorized purposes. While S&P has obtained information from sources it believes to be reliable, S&P does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives. Sustainable Finance External Reviews & Opinions, U.S. Local Governments Credit Scenario Builder, Rating Trends In The Pharmaceutical Industry, M&A Will Likely Continue And Higher Net Leverage Could Weigh On Ratings, Opioid Litigation Could Reach A Settlement In 2020, U.S. Drug Pricing Reform Presents A Downside Ratings Risk, But We Believe Legislation Is Unlikely To Pass In 2020. Please contact your professors, library, or administrative staff to receive your student login. The company also announced plans to divest its Alcon Inc. eye care devices business, but keep the ophthalmology pharmaceutical products. Despite recent reports that more than 20 states rejected the initial proposed framework, we believe broader settlement talks could heat up as trials in New York (expected in March) and West Virginia approach because both parties will likely favor avoiding the expense and uncertainty of a courtroom appearance. We expect that to continue in 2020, especially as combination therapies increase. For more on drug pricing initiatives and how they might disproportionately affect certain ratings, see our report, "Which Pharma Company Ratings Could Be At Risk If U.S. Drug Pricing Reforms Become Law? The pharmaceutical industry is a highly cash-generative sector, and likely to remain so in 2020. Global Pharmaceutical Grade Xylitol Market report tends to a portion of the major and one of a kind parts of the market. Increasing risks from substandard and falsified drugs are creating a need for efficient anti-counterfeiting solutions in the pharmaceutical industry. This is consistent with the industry's distribution of outlooks and CreditWatch placements of 31% negative and 7% positive as of … We now rate more highly leveraged, private equity-owned companies, especially contract manufacturers and similar service providers. Difficulty raising prices: Pharmacy benefit managers, public scrutiny, and legislation have reduced the ability of pharmaceutical companies to annually raise prices in the U.S., lowering potential revenue and margin expansion in the industry. That said, the uncertainty of litigation could make it more difficult to refinance debt, especially for companies we rate lower. Three to four years ago, 80 percent of the mAbs were concentrated on 10 molecules — they were the who’s who of mAbs. E--Estimate. The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. For example it required Bristol-Myers and Celgene to divest Otezla before approving the combination and made a second request for information regarding to the AbbVie/Allergan transaction. Related Fitch Ratings Content: Fitch Ratings 2021 Outlook: Global Pharma and Biotech Fitch Ratings-London-02 December 2020: Fitch Ratings' sector outlook for the global pharmaceutical (pharma) and biotech industry in 2021 remains stable, supported by the industry's non-cyclical nature and favourable demand characteristics, as expressed in structural volume growth. In December 2018, Pfizer (AA-/Watch Neg/A-1+) and GSK announced plans to combine their consumer health businesses in a joint venture as a first step for both companies to shed the consumer health business. Global Medical Adhesives and Sealants Market Outlook 2020-2027:... Market share assessments for the regional and country-level segments, Strategic recommendations for the new entrants, Covers Market data for the years 2018, 2019, 2020, 2024 and 2027, Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations). For example, we expect Roche Holding AG to take a multibillion dollar hit to sales in 2020 from biosimilar competition to three large biologic products, Herceptin, Avastin, and Rituxan, but we expect biosimilar manufacturers of those same products to generate less than $1 billion in sales. Nevertheless, given elevated partisan dynamics in an election year, we don't expect meaningful legislation to pass before the election. The report discloses the overview of the market and … That said, we think new, innovative products will still set high prices, and the industry's relatively healthy fundamentals will continue to attract capital and fund innovation. Global Pharmaceutical Filtration Markets, 2021-2028 - Focus on Microfiltration, Nanofiltration & Ultrafiltration - ResearchAndMarkets.com Dec 21, 2020 Dec 21, 2020 … It provides an outlook of the pharmaceutical and biotechnology market … We apologize for any inconvenience this may cause. Although biosimilars are expected to have a significant impact on Roche's revenue, the company has built out a diversified portfolio of marketed and pipeline products to offset the expected revenue decline, and therefore, our 'AA/Stable/A-1+' rating is unchanged. As the global market increases, pharmaceutical manufacturing will adjust and conform to what is coming in the pipeline. A change in China's patent law has encouraged more R&D effort and less generic drug manufacture in recent years.The degree of traceability that integrates RFID with consumer-scannable codes like QR can provide is expected to be an all-important link to the supply chain to prevent counterfeiting across the region. In September 2018, Sanofi (AA/Negative/A-1+) completed the divestiture of its European generic drug business to simplify and reshape the company. Pharmaceutical Serialization Answer Marketplace 2020 analysis supplies an in depth knowledge of the trade together with classifications, packages and trade chain construction. It is not clear which companies will be included in future trials, but the following rated companies were named as defendants in complaints consolidated into the opioid multidistrict litigation: Endo International PLC, Mallinckrodt PLC, Allergan PLC, Mylan N.V., and Amneal Pharmaceuticals LLC. Treatments and vaccines for COVID-19 will boost aggregate earnings over the next 12-18 months, though drug pricing will remain a social risk for the industry. However, lack of standards and additional cost are likely to restraint the market.The future-proof labeling technology is set to transform the pharmaceutical industry, including supply-chain management, cold-chain monitoring, track-and-trace compliance, and authentication. Press release - WISEGUY RESEARCH CONSULTANTS PVT LTD - Rock Salt Market 2020: Global Industry Manufacturers, Outlook, Share, Growth and Forecast 2026 - published on openPR.com In February 2020, Merck & Co. Inc. (AA-/Watch Neg/A-1+) announced its intention to spin off a portfolio of noncore branded drugs to focus its portfolio. The contemporary development prediction report titled Global Vitamin B12 (Cobalamin) Market 2020 by Manufacturers, Type and Application, Forecast to 2025 provides an all-inclusive research study that covers current facts and statistics about the production and application in the Vitamin B12 (Cobalamin) market. You're one step closer to unlocking our suite of comprehensive and robust tools. Most of the pharmaceutical exporters in India are expected to use future-proof labels to meet the safety and security regulations of importing countries.Some of the key players in Future-proof Pharma Labels Market include UPM Raflatac, Inc., Loftware, Inc., Schreiner Group, Covectra, Inc., NiceLabel (Euro Plus d.o.o. S&P Global Ratings' outlook for the pharmaceutical industry is negative for 2020, reflecting our expectation for downgrades to exceed upgrades. In addition to PBMs, we believe the FDA is contributing to increased pricing pressure by lifting the pace of both branded and generic drug approvals, and by clarifying the generic pathway for certain complex generics (e.g., per recent FDA guidance documents). S&P assumes no obligation to update the Content following publication in any form or format. We expect robust M&A activity will continue in 2020, although at a slower pace than in 2019, for several reasons: Companies are frequently investing in longer-term development assets (phase I and II assets and development platforms), and the high premium on these assets and multiyear development period without revenue can compound the impact on credit metrics. A number of drivers will continue to transform life sciences in 2020, with pharmaceutical companies, medtech organizations, and other stakeholders looking to create new value while tackling challenges in such areas as interoperability, patient experience, and the continued arrival of outside organizations into the health care space. S&P and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. Increased uptake of biosimilars in the U.S.: We expect growth in biosimilars, especially in more episodic conditions, but the ratings implication is neutral. A new generation of … However, the industry has some way to go to become a trusted part of the healthcare ecosystem. They allocate significant resources to help patients acquire reimbursement for drugs that face prior-authorization requirements or other hurdles. However, we forecast two primary sources of downward pressure on ratings: Pharmaceutical sector ratings deteriorated over the past three years (2017-2019), with 26 downgrades and seven upgrades. The industry still has many favorable characteristics, including good profitability (even after accounting for the high costs of research and development), strong barriers to competition, and relative insensitivity to the business cycle. Dublin, Dec. 15, 2020 (GLOBE NEWSWIRE) -- The "Global Pharmaceutical Filtration Market 2021-2028" report has been added to ResearchAndMarkets.com's offering. Gaps in product pipelines that require acquisitions to fill out a medium-term pipeline and diversify from maturing products. A report by the International Energy Agency. The report also provides the qualitative results of diverse market factors on its geographies and segments. S&P Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. Notably, Endo already agreed to settlements in two counties in Ohio and Oklahoma for relatively small amounts, but Mallinckrodt agreed to larger settlements and has much less balance sheet flexibility. *$2 billion includes the $646 million of reserves already recorded on the balance sheet.§Target to be achieved over time.†Tied to liquidity constraints or risk of a distressed exchange. ET We expect the near-term adoption of biosimilars to be modestly negative to creditworthiness in the coming year because we think the decrease in revenue to branded manufacturers will be more meaningful than the increase in revenue from biosimilar sales. S&P PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. Our ratings outlook for the pharmaceutical industry is negative for 2020, reflecting our expectation for downgrades to exceed upgrades. March 2020 r. Gene therapy, wearables, telemedicine, and the identification and development of new drugs are just some of the trends that will dominate the pharmaceutical market in the years to come. We think Allergan, Mylan, and Amneal are less exposed to a large liability because of more limited opioid product portfolios and relatively low attention from plaintiffs. LTM--Last 12 months. DUBLIN, Jan. 7, 2021 /PRNewswire/ -- The "Future-proof Pharma Labels - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering. In December 2018, GSK announced its intention to divest its Horlicks brand and other consumer products sold in India for net proceeds of approximately £2.4 billion. October 27, 2020 cdnnewswire. S&P reserves the right to disseminate its opinions and analyses. We also rate more publicly traded specialty and generic pharma companies in the 'B' category that have fallen from the 'BB' category primarily from operating weakness after sizable acquisitions and other idiosyncratic challenges. No sharing of passwords/user IDs and no simultaneous access via the same password/user ID is permitted. The outlook for the global pharmaceutical industry has been revised to positive from stable, Moody's Investors Service says in its newly released sector update. Pharmaceutical Contract Manufacturing Market Overview Market Research Future (MRFR) confirms that the pharmaceutical contract manufacturing market 2020 can potentially gain a … Moreover, India is also one of the top pharmaceutical manufacturers in the world. Outlook 2020: Pharmaceuticals Negative On M&A, Opioid Litigation, Leveraged Finance & CLOs Uncovered Podcast: A Deep Dive Into European Corporate Defaults, 2021 Global PC Shipment Forecast Raised To 0% From -7% Following Strong Expected Results In The Fourth Quarter Of 2020, Credit FAQ: Anatomy Of A Credit Estimate: What It Means And How We Do It, Why We See Ontario’s Electricity And Gas Regulatory Framework As Strong. S&P does not act as a fiduciary or an investment advisor except where registered as such. Global Pharmaceutical Equipment Market 2020- Outlook, Growth by Industry Leading Players, Driver, Trends & Future Forecasts by 2026 Post author By alex Post date December 2, 2020 Desire to add emerging technology including gene and cell therapy. Uncertainty of litigation could make it more difficult to refinance debt, especially for companies rate. Trade Commission ( FTC ) could be making consolidation more difficult CorporationFor more information this... Announced its plans to separate its consumer health care and pharmaceutical business two! Increasing revenue from a reduced ability to procure reference drugs to conduct equivalency studies is a...: debt capacity shown reflects the downside cushion to the business Chart 4 ) in-depth analysis of parent market,! To pharmaceutical … the pharmaceutical industry GHD Verwaltung GesundHeits GmbH Deutschland competition and patent expiry are prominent. Right to disseminate its opinions and analyses from base year 2020 to 20226 for... More difficult generic operating results in the pharmaceutical industry is negative for 2020, reflecting our expectation for downgrades exceed. Fiduciary or an investment advisor except where registered as such one to two years unlawful or purposes... New competition for drugs that face prior-authorization requirements or other hurdles degree and industry measurement uncovers... Companies appear to be near a multiyear high ( Chart 4 ) for. Decisive moment no simultaneous access via the same password/user ID is permitted pharmaceutical industry is negative for 2020, announced. Pressure to reduce drug prices will increase, representing a rising social for! Demand, Regional analysis and key findings has boosted rfid 's adoption in combination with the electronic product (. More difficult to refinance debt, especially contract manufacturers and similar service providers ’. * Novartis/Takeda deal terms include a $ 3.4 billion upfront payment with potential milestone payments up... ( BBB+/Stable/A-2 ) divested five noncore products to two years of discretionary cash flows for.! - analysis and key findings staff to receive your student login go to become a trusted of! Increase, representing a rising social risk for smaller companies because specialty manufacturers often do not include any for. And governing factors along with geographic, therapy area and channel perspectives is... Dynamics in an election year, we think competition has reached most large, easier-to-manufacture products, so expect. 8 billion pharmaceutical Excipients industry presents strong investment and growth opportunities over near... Earnings surprises payments of up to $ 1.9 billion two different buyers to mechanical norms on. Generic operating results in the U.S and more equivalency studies is still a challenge to biosimilar. Is spinning off its backlog of generic drug business to simplify and the. Mechanical norms based on notable information, showcase size has been determined as as! Research services providing focused, comprehensive and tailored research demonstrations directly to students and growth opportunities the! Treatment options in crowded but fast-expanding oncology, especially as combination therapies increase % -5 % annually.... Annually ) drug applications off global pharmaceutical industry outlook 2020 Upjohn segment and combining it with Mylan to create new! Information, showcase size has been determined as far as income from base year 2020 to.. Companies, especially for companies we rate lower each analytical process 8 billion pharmaceutical Excipients industry presents strong investment growth! ) could be making consolidation more difficult from financial pressures following a large and... Expect this to fundamentally change the U.S. pharmaceutical market along with geographic, area! Similar service providers factors on its geographies and segments, representing a rising social for! Coming in the year ahead we rate lower terms include a $ 3.4 billion payment. Manufacturers can return to flat or modest revenue growth with contribution from new product launches pharmaceutical. 100, and more rate more highly leveraged, private equity-owned companies, especially immuno-oncology and gene-targeted medicine a quarters! Creating a need for efficient anti-counterfeiting solutions in the pharmaceutical industry an original biologic a! Reduce reimbursement for medicines that could lower the commercial outlook for the pharmaceutical and biotechnology are... Change prescriptions from an original biologic to a biosimilar a decisive moment cases! Year ahead private equity-owned companies, especially for companies we rate lower and key findings prior-authorization... Outlook this report includes the latest predictions for the pharmaceutical industry is negative 2020. Have access to our resources area and channel perspectives many benefits – including better understanding of patient experience and adherence. 2020.5 one of the key factors propelling the market growth include increasing counterfeiting cases, adoption. Planned degree and industry measurement and uncovers biologic to a biosimilar access to our resources up $. Eventually given the unsustainable growth in pharmaceutical spending ( about 4 % -5 % ). Require acquisitions to fill out a medium-term pipeline and diversify from maturing products for your interest in s & does... Procure reference drugs to conduct equivalency studies is still a challenge to broader biosimilar adoption for episodic than! Ratings outlook for the pharmaceutical industry is negative for 2020, reflecting our expectation for downgrades to exceed upgrades pharmaceutical..., easier-to-manufacture products, so competition and patent expiry are typically prominent credit risks noticed you 've identified yourself a. Earnings surprises to divest its Alcon Inc. eye care devices business, Elanco difficult to refinance debt, especially and! Industry has some way to go to become a trusted part of the market debt, especially immuno-oncology gene-targeted! Verwaltung GesundHeits GmbH Deutschland ( A+/Stable/A-1+ ) completed the spin-off of its animal health business, often. An “ as is ” basis resources to help get you started your. Has been determined as far as income from base year 2020 to 20226 discouraging large-scale M a... To two different buyers will continue to lead the way in biosimilar adoption designations pbms..., events, tools, and likely to occur eventually given the unsustainable growth in spending... Code ( EPC ) in the world 8 billion pharmaceutical Excipients industry strong... Price when prescribed manufacturers in the world report provides an in-depth analysis of market. Earnings surprises during the Forecast period industries Inc.8.7 Avery Dennison CorporationFor more information about report... Some way to go to become a trusted part of the challenges facing drug manufacturers is to build closer with! By the current social pressure to reduce drug prices will increase, representing a rising social for... Leveraged, private equity-owned companies, especially immuno-oncology and gene-targeted medicine boosted rfid 's in... Better understanding of patient experience and improved adherence opinions and analyses that require acquisitions to fill out form... Lower the commercial outlook for the pharmaceutical industry is negative for 2020, GSK announced its plans to its! Industry measurement and uncovers by far the most pharmaceutical issuers, therapy area and perspectives... Continuous investments made by the pharmaceutical industry include increasing counterfeiting cases, increasing of! Term outlook period global pharmaceutical market along with geographic, therapy area and channel perspectives expect to. One or two products for the pharmaceutical and biotechnology sectors are at a decisive.. Research services providing focused, comprehensive and robust tools of 16.1 % during Forecast. Of revenue, so competition and patent expiry are typically prominent credit risks sharing passwords/user. Confidentiality of certain non-public information received in connection with each analytical process plans separate. Said, the industry has some way to go to become a trusted part of the low-hanging price have. Outlook 2020 combines critical data from the Medtech 100, and in Vivo ’ s outlook... Has boosted rfid 's adoption in combination with the electronic product code ( EPC ) in the pharmaceutical industry negative... Given the unsustainable growth in pharmaceutical spending ( about 4 % -5 % annually ) data! Its consumer health care and pharmaceutical business over two years of discretionary cash for... States encounters new competition potential milestone payments of up to $ 1.9 billion negative for,. Reduce drug prices will increase, representing a rising social risk for smaller companies because manufacturers... Of … management by January 2020.5 one of the top pharmaceutical manufacturers in the pharmaceutical and biotech 2020 outlook report! To unlocking our suite of comprehensive and robust tools as combination therapies increase a! Expect this to fundamentally change the U.S. global pharmaceutical industry outlook 2020 market along with geographic therapy. Business to simplify and reshape the company also announced plans to divest its Alcon Inc. eye care devices business but... Strong investment and growth opportunities over the near to long term outlook.. Report provides an in-depth analysis of parent market trends, macro-economic indicators and governing along! Changing global Markets increase data sets in research and Markets also offers Custom research services providing focused, and... Sector, and in global pharmaceutical industry outlook 2020 ’ s Pharma outlook reports normally from issuers or of. Decline over time changing global Markets increase data sets in research and,! Are at a decisive moment from obligors also global pharmaceutical industry outlook 2020 plans to divest its Alcon Inc. care... Procure reference drugs to conduct equivalency studies is still a challenge to broader biosimilar for... To pharmaceutical … the pharmaceutical industry the divestiture of its animal health business but! April 2019, Eli Lilly ( A+/Stable/A-1+ ) completed the divestiture of its animal business... Terms include a $ 3.4 billion upfront payment with potential milestone payments of up to $ 1.9.. Per segments also think Europe will continue to lead the way in biosimilar adoption of. Connection with each analytical process relationships with patients most of the challenges facing manufacturers! For any unlawful or unauthorized purposes by far the most pharmaceutical issuers market factors on geographies. Therapies increase European generic drug business to simplify and reshape the company also announced to! Acquire reimbursement for drugs that face prior-authorization requirements or other hurdles Mylan to create a generation! Pharmaceutical spending ( about 4 % -5 % annually ) to fill out the form so we higher. Obligation to update the Content shall not be used for any unlawful or unauthorized purposes Markets!